Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL
Bank of America Corp DE significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 31.3% in the first quarter, now holding 580,875 shares valued at $19.39 million. This move comes as institutional investors collectively own 97.7% of the company. Despite positive analyst sentiment with a "Moderate Buy" consensus, recent price target reductions and mixed earnings forecasts indicate a cautious outlook for Omnicell's stock performance.
Zacks Research Has Bearish Estimate for Omnicell Q3 Earnings
Zacks Research has issued a "Strong Sell" rating for Omnicell (NASDAQ:OMCL) and reduced its Q3 2026 EPS estimate to $0.25 from $0.27. Despite the near-term bearish outlook, Zacks projects a full-year 2026 EPS of $1.49, exceeding the broader consensus, but has lowered its FY2027 forecast to $1.27. Institutional investors hold a significant 97.7% stake in the company, which recently reported better-than-expected earnings and revenue for its latest quarter.
Rice Hall James & Associates LLC Invests $2.15 Million in Omnicell, Inc. $OMCL
Rice Hall James & Associates LLC has invested approximately $2.15 million in Omnicell, Inc. (NASDAQ:OMCL) by acquiring 51,789 shares, representing about 0.11% of the company. Omnicell has garnered a "Moderate Buy" rating from analysts with an average target price of $57.86, despite some recent price target adjustments. The company recently surpassed quarterly earnings expectations, reporting $0.94 EPS against a $0.47 consensus and revenue of $312.21 million.
Omnicell (OMCL) Slides On Valuation Debate, Is The Stock Cheap?
Omnicell (OMCL) has seen its share price decline significantly over the past month, leading to a debate about its valuation. While some analyses suggest it is undervalued with a fair value of $61.29 based on its shift to recurring SaaS revenue, others point to its high P/E ratio of 42.1x compared to industry averages, indicating potential overvaluation. Investors are encouraged to review underlying numbers and consider risks before making investment decisions.
Omnicell (OMCL) Slides On Valuation Debate, Is The Stock Cheap?
Omnicell (OMCL) has seen its share price fall by 21% in the past month and 18% over the last three months, raising questions about its valuation. While analyst narratives suggest the stock is undervalued with a fair value of $61.29 due to its OmniSphere platform's shift to recurring SaaS revenues, its current P/E ratio of 42.1x is higher than the industry average, implying potential valuation risk. Investors are advised to examine the underlying numbers and consider both potential rewards and risks.
Omnicell (NASDAQ: OMCL) CEO withholds stock to cover RSU taxes
Omnicell's Chairman and CEO, Randall A. Lipps, reported withholding 12,350 shares of Common Stock at $37.30 on August 15, 2026, to cover tax obligations from vesting restricted stock units. Following this transaction and an Employee Stock Purchase Plan acquisition, Lipps directly holds over 511,000 shares and indirectly holds additional shares in trusts. This event is categorized as a neutral insider transaction with moderate filing impact.
Omnicell (OMCL) legal chief has 4,025 shares withheld for taxes
Omnicell's Executive Vice President and Chief Legal/Administrative Officer, Corey J. Manley, had 4,025 shares of common stock withheld to cover taxes related to the vesting of restricted stock units on August 15, 2026. The reference price for these shares was $37.30. Following this transaction and an additional purchase of 226.4621 shares through an Employee Stock Purchase Plan, Manley now directly holds 108,984.8013 shares of Omnicell common stock.
Omnicell (NASDAQ: OMCL) insider plans sale of 3,083 shares
Omnicell insider Nnamdi T. Njoku has filed a notice of intent to sell 3,083 shares of common stock, valued at $113,608.55, through Fidelity Brokerage Services LLC. These shares are compensation-related, stemming from restricted stock vesting on August 15, 2026. Njoku previously sold 3,090 shares for $133,549.80 on May 18, 2026.
Omnicell, Inc. $OMCL Shares Acquired by Empowered Funds LLC
Empowered Funds LLC significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4,229.9% in the first quarter, now owning 262,043 shares valued at $8.7 million. This comes as other institutional investors have also adjusted their positions in the healthcare technology company. Insider transactions show Omnicell executives Nnamdi Njoku and Corey J. Manley sold shares to cover tax obligations, while analysts maintain a "Moderate Buy" consensus rating for the stock.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has increased its 2026 earnings outlook after a strong second quarter, partially boosted by a one-time tariff refund. The company faces a $6 million headwind from rising memory-chip costs but plans to offset this with operational discipline and cost control. Despite a "Strong Sell" Zacks Rank, the stock shows favorable growth, value, and momentum characteristics.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control and operating efficiency to absorb these pressures. Omnicell's updated guidance also includes widened product bookings and a reduction in annual recurring revenue expectations due to slower development of certain opportunities and lengthy hospital approval cycles.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell (OMCL) shares have dropped 20.1% in the past month despite raising its 2026 profit outlook, due to concerns over bookings timing, recurring-revenue growth, rising component costs, and the pace of its product refresh. While the company's Q2 2026 earnings beat estimates, new pressures from memory-chip costs and a slower-than-expected refresh cycle are affecting margins and revenue predictability. Despite a low valuation, the Zacks Rank currently signals caution due to short-term uncertainties.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell (OMCL) shares have
Quantinno Capital Management LP Has $1.92 Million Position in Omnicell, Inc. $OMCL
Quantinno Capital Management LP significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 390.2%, now holding 57,560 shares valued at $1.92 million. This move comes as institutional investors collectively own 97.7% of the company, and analysts maintain a "Moderate Buy" rating despite recent price target adjustments. Omnicell recently surpassed earnings estimates with an EPS of $0.94 and a 7.4% year-over-year revenue increase.
(OMCL) Price Dynamics and Execution-Aware Positioning
Omnicell Inc. (NASDAQ: OMCL) is exhibiting choppy conditions due to divergent sentiment across all time horizons, with support currently being tested. The AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each tailored for different risk profiles. The analysis highlights an exceptional 72.8:1 risk-reward setup targeting a 20.3% gain versus 0.3% risk if support holds.
Millennium reports 3.8% Omnicell (OMCL) stake in amended 13G filing
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have collectively reported a beneficial ownership of 1,734,375 shares of Omnicell, Inc. (OMCL) common stock, which represents 3.8% of the outstanding class. This disclosure was made in an amended 13G filing, indicating shared voting and dispositive power over these shares, with no single entity holding sole control. The filing confirms their stake is below the 5% threshold, categorizing it as a passive investment.
Does Omnicell’s Profit Rebound And Higher 2026 Outlook Change The Bull Case For OMCL?
Omnicell, Inc. reported strong Q2 2026 results with increased revenue and net income, alongside upgraded guidance for the full year 2026. This improved profitability and higher revenue outlook strengthen the company's investment narrative, which relies on medication management automation and a growing software and services mix. However, the analysis also notes potential short-term risks from hospital budget pressures that could impact automation and SaaS adoption.
Omnicell (OMCL) Could Be 40% Undervalued Following Strong Q2 Earnings And Guidance Raised
Omnicell (OMCL) reported strong Q2 2026 earnings, leading to a rebound in its stock price and updated full-year revenue guidance. The company is considered undervalued by Simply Wall St's narrative, with a fair value of $61.29 compared to its current price of $36.81, driven by expectations of growth from its OmniSphere platform and a shift to higher-margin SaaS revenues. However, its P/E ratio is currently higher than the industry average, suggesting potential caution for investors.
Omnicell (NasdaqGS:OMCL) Stock Forecast & Analyst Predictions
This article provides an in-depth analysis of Omnicell's (OMCL) stock forecast and analyst predictions, highlighting expected earnings and revenue growth, key financial updates, and recent market activities. It covers various updates including earnings guidance, price target changes, leadership appointments, and new product launches like Omnicell Titan XT, alongside insider transactions and risk assessments. The report indicates a mixed analyst sentiment but generally points to future growth driven by new product cycles and an expanding service business.
Royal Bank of Canada Sells 78,803 Shares of Omnicell, Inc. $OMCL
Royal Bank of Canada reduced its stake in Omnicell, Inc. by 12.9%, selling 78,803 shares but still retaining 532,172 shares valued at approximately $17.8 million. Other institutional investors have also adjusted their positions, and Omnicell reported strong quarterly earnings, beating analyst estimates with a 7.4% year-over-year revenue increase. The company maintains a "Moderate Buy" consensus rating from analysts, despite a recent dip in its stock price.
First Trust Advisors LP Has $2.85 Million Stake in Omnicell, Inc. $OMCL
First Trust Advisors LP significantly reduced its stake in Omnicell, Inc. during the first quarter, selling over 46,000 shares but still retaining a $2.85 million position. Despite this reduction, institutional investors collectively own a substantial 97.7% of OMCL. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $57.86, following Omnicell's recent earnings beat.
OMNICELL, INC. 2026: Revenue $312.21M, EPS $0.52— 10-Q Summary
Omnicell, Inc. (OMCL) reported strong financial results for the quarter ended 2026, with revenue reaching $312.21M and diluted EPS of $0.52. This growth was driven by increased product and service sales, improved margins, and strategic shifts towards platform offerings and recurring revenue. The company also highlighted investments in R&D and expanded services to support long-term automation adoption.
OMCL|Omnicell Inc|Price:37.525|Chg%:+2.155
This article provides a comprehensive stock analysis of Omnicell Inc (OMCL), highlighting its relatively healthy fundamentals, significant growth potential, and fair valuation. Despite recent weak stock market performance, the company maintains strong fundamentals, and analysts have issued "Buy" ratings with a high price target. The report details Omnicell's business, key financial metrics, institutional ownership, and a peer comparison within the Healthcare Equipment & Supplies industry.
Weekly Recap: Omnicell, Inc. Q3/2026 revenue and analyst price target
Omnicell, Inc. (OMCL) reported Q3 revenue between $301-$307 million and guided 2026 revenue to $1.225-$1.245 billion, with an estimated year-end ARR of $660-$680 million. Analysts are optimistic, with a median 12-month price target of $60, suggesting a 31% upside, and the company recently appointed new executives including a President and COO.
Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability
Omnicell (OMCL) reported stronger Q2 2026 revenue and net income, alongside improved profitability for the first half of 2026. The company also raised its full-year 2026 revenue guidance to between US$1.23 billion and US$1.25 billion, signaling higher expectations. Despite the positive outlook, the stock declined by 12.5%, and the article discusses the investment narrative, risks from tariffs and hospital budgets, and varying analyst forecasts.
Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability
Omnicell (OMCL) reported strong second-quarter 2026 revenue and net income, showing improved profitability for the first half of the year. The company raised its full-year 2026 revenue guidance to US$1.23 billion to US$1.25 billion, reflecting management's higher expectations despite a 12.5% stock drop. This positive outlook is driven by anticipated growth in automation and software in healthcare, though risks like tariffs and hospital budget pressures remain.
Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability
Omnicell, Inc. (OMCL) reported improved financial results for Q2 2026, including increased revenue and a return to profitability, leading them to raise their full-year 2026 revenue guidance to US$1.23 billion to US$1.25 billion. Despite these positive developments, the stock price fell by 12.5%. The article discusses the investment narrative for Omnicell, emphasizing the reliance on hospital and pharmacy automation investment, while also considering risks like tariffs and hospital budget pressures, and analyst perspectives on future growth and profitability.
Omnicell Promotes Chief Operating Officer Nnamdi Njoku to President
Omnicell has promoted its Chief Operating Officer, Nnamdi Njoku, to President, expanding his role to include directing long-term growth, product development, and overseeing global operations. Njoku, who joined Omnicell less than two years ago, will also lead the launch of the Titan XT system and expansion of the OmniSphere platform. CEO Randall Lipps will focus more on customer relationships, strategic partnerships, and product portfolio development.
ETFs Investing in Omnicell, Inc. Stocks
This article lists various ETFs that hold Omnicell, Inc. (OC9) stocks, sorted by market value. It provides key details for each ETF, such as issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs predominantly target small-cap and healthcare sectors, with some also focusing on themes like robotics and artificial intelligence.
Price to earnings forward of Omnicell, Inc. – NASDAQ:OMCL
This article provides financial information for Omnicell, Inc. (NASDAQ: OMCL), specifically focusing on its forward price-to-earnings ratio. It lists the company's stock market details, financial overview, and acknowledges the data sources used.
Omnicell (OMCL) Stock Falls As Tariff Boost Clouds Profit Strength
Omnicell's stock fell 4.7% despite beating non-GAAP earnings guidance, largely due to a one-time tariff refund. While the company emphasizes its transition to recurring revenue through services and strategic products, bears highlight execution risks, volatile product bookings, and the impact of non-recurring items on reported profits. The article suggests investors assess Omnicell's financial health to determine if its cash generation truly supports its high P/E ratio.
Is Omnicell Inc (OMCL) a Bargain After 4.7% Drop? GF Value Says Undervalued
Omnicell Inc (OMCL) shares dropped 4.7%, bringing its price to $35.37, which is 8.9% below its GF Value™ of $38.82, suggesting it is undervalued. The company's GF Score™ is 75/100, with strong valuation but weak growth. Despite the undervaluation, recent insider selling and mixed guru activity suggest caution for investors.
Omnicell (OMCL) Stock Trades Down, Here Is Why
Omnicell (OMCL) stock fell 9.9% in the afternoon session after the company issued weak guidance for the upcoming quarter, despite reporting strong second-quarter results that beat Wall Street's expectations. The projected third-quarter revenue of approximately $304 million was 2.9% below analysts' estimates, and earnings per share guidance also missed consensus expectations, raising concerns about its near-term growth trajectory. This follows a previous significant drop six months ago due to disappointing fourth-quarter earnings and a weak forecast for the 2026 financial year.
OMNICELL INC. : WELLS FARGO CUTS TARGET PRICE TO $50 FROM $55
Wells Fargo has reduced its target price for OMNICELL INC. (OMCL.O) shares from $55 to $50. This change was reported by Reuters on July 31, 2026. The article provides this update without further elaboration or analysis.
Omnicell Q2 Earnings Call Highlights
Omnicell (NASDAQ: OMCL) reported strong Q2 2026 results, surpassing profitability expectations with $312 million in revenue and $0.94 non-GAAP EPS, partly due to a $15 million tariff refund. The company updated its full-year product bookings guidance to $425 million–$560 million, attributing the widened range to extended customer approval cycles rather than reduced demand. Omnicell also raised its full-year profitability outlook despite lowering revenue expectations and anticipating increased costs from memory-chip supply pressures.
Omnicell Inc (OMCL) (Q2 2026) Earnings Call Highlights: Strong Profitability and Strategic Wins ...
Omnicell Inc. (OMCL) reported strong Q2 2026 results with revenues at the high end of guidance and EPS well above expectations, driven by favorable revenue mix and cost management. Despite this, the company revised its full-year product bookings guidance to a wide range due to lengthening customer decision cycles for large enterprise deals and lowered ARR guidance. Omnicell secured its first competitive Titan XT conversion win and is expanding leasing programs, showcasing confidence in its platform strategy despite anticipated incremental costs from memory chip supply imbalances.
Stronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)
Omnicell (OMCL) reported stronger Q2 2026 results with increased revenue and net income, alongside improved full-year 2026 revenue guidance of US$1.23 billion–US$1.25 billion. This updated outlook provides clearer insights into the company's near-term growth, potentially reshaping its investment narrative. Despite the positive guidance, investors are cautioned about ongoing risks related to tariff costs and potential hospital budget constraints, urging a thorough assessment of the company's financial health.
Omnicell (OMCL) Stock Trades Down, Here Is Why
Shares of Omnicell (OMCL) fell 9.9% after the company issued weak guidance for the upcoming quarter despite reporting strong second-quarter results that beat Wall Street expectations. The healthcare technology company projected third-quarter revenue below analysts' estimates and its EPS guidance also missed consensus, raising concerns about near-term growth. The stock has been volatile, previously dropping 18.4% six months ago due to disappointing Q4 earnings and a weak forecast for the 2026 financial year.
GUIDANCE: (OMCL) Omnicell, Inc. Expects Q3 Adjusted EPS Range $0.35 - $0.43
Omnicell, Inc. (OMCL) has issued guidance for its third-quarter adjusted EPS, anticipating a range of $0.35 to $0.43. This guidance provides investors with an outlook on the company's expected financial performance for the upcoming quarter.
Omnicell Announces Second Quarter 2026 Financial Results
Omnicell, Inc. reported solid financial results for the second quarter of 2026, with total revenues of $312 million, a 7% increase from the previous year. The company saw a significant improvement in GAAP net income and non-GAAP net income per diluted share, partly due to $15 million in tariff refunds. Omnicell also updated its full-year 2026 guidance, raising forecasts for non-GAAP EBITDA and non-GAAP earnings per share, and announced executive promotions and new roles to support long-term growth.
Omnicell (OMCL) Q2 Earnings and Revenues Top Estimates
Omnicell (OMCL) reported Q2 earnings of $0.94 per share, significantly exceeding the Zacks Consensus Estimate of $0.48, and revenues of $312.21 million, also topping estimates. Despite these strong results, Omnicell shares have fallen 8.6% year-to-date, contrasting with the S&P 500's 6.9% gain. The company holds a Zacks Rank #3 (Hold) as the market awaits further guidance from management.
Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance
Omnicell (NASDAQ:OMCL) reported Q2 CY2026 earnings, beating Wall Street's revenue and EPS estimates with sales up 7.4% year-on-year to $312.2 million and non-GAAP EPS of $0.94. Despite the Q2 beat and raised full-year EBITDA and EPS guidance, the stock dropped 5.6% due to weaker-than-expected revenue guidance for the next quarter. The market reacted negatively to the outlook, indicating a mixed quarter overall.
Why is Omnicell stock rallying today?
Omnicell stock initially surged after reporting strong Q2 2026 earnings, significantly beating analyst estimates for both EPS and revenue. However, the rally was short-lived as the company's Q3 and full-year guidance fell below market expectations, leading to a subsequent pullback and erasing most of the intraday gains. This "beat-and-lower" dynamic reflected investor enthusiasm for past performance tempered by concerns over future growth.
Earnings Flash (OMCL) Omnicell, Inc. Posts Q2 Adjusted EPS $0.94 per Share, vs. FactSet Est of $0.47
Omnicell, Inc. (OMCL) announced its Q2 adjusted earnings per share (EPS) of $0.94, significantly surpassing the FactSet estimate of $0.47. The company's Q2 revenue also exceeded expectations, reporting $312.2 million against an estimated $310.2 million. Omnicell further provided a Q3 revenue outlook ranging from $301.0 million to $307.0 million and an adjusted EPS range of $0.35 to $0.43.
Omnicell (NASDAQ: OMCL) Q2 profit jumps as 2026 guidance raised
Omnicell (NASDAQ: OMCL) reported strong second-quarter 2026 results, with total revenues up 7% to $312 million and GAAP net income increasing to $24 million. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP EPS guidance and tightened its revenue outlook. The positive results were attributed to demand for connected devices, SaaS and services, disciplined costs, and a $15 million refund from previously paid IEEPA tariffs.
Omnicell earnings on deck: Can Titan XT launch sustain momentum?
Omnicell Inc. is set to report its second-quarter results, with analysts anticipating earnings of 47 cents per share on revenue of $310.25 million. Investors will be focused on the performance and adoption rates of the newly launched Titan XT cabinet system, which is seen as a key catalyst for the healthcare automation company. The company also recently promoted COO Nnamdi Njoku to President, with responsibility for driving global operations and key platforms.
Omnicell (OMCL) Reports Q2: Everything You Need To Know Ahead Of Earnings
Omnicell (OMCL) is set to announce its Q2 earnings this Thursday morning. The company previously exceeded revenue expectations, reporting $309.9 million, a 14.9% year-on-year increase, and beat analysts' EPS estimates. For the upcoming quarter, the market anticipates a 6.8% year-on-year revenue growth, and analysts have largely maintained their estimates.
Omnicell (OMCL) Could Be 30% Undervalued If Its OmniSphere Shift Pays Off
Omnicell (OMCL) is attracting attention due to recent share price movements and its strategic shift towards the cloud-native OmniSphere platform, which aims to simplify medication management and boost recurring SaaS-based revenues. While a popular narrative suggests the company is 29.8% undervalued with a fair value of $61.29, its high P/E ratio of 95.8x compared to industry averages raises questions about its current valuation. The article advises investors to thoroughly review data and stress test assumptions regarding Omnicell’s growth and profitability.
Omnicell Inc (OMCL) Earnings Forecast: Future EPS & Revenue Growth Estimates
Omnicell Inc (OMCL) currently has an earnings forecast score of 8.00, placing it 68th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $47.00, with a majority recommending a "Buy" trend for the stock. The company's expected revenue for the next quarter is $310.25 million, and its EPS for the upcoming quarter is projected at $0.47.
Omnicell Inc (OMCL) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Omnicell Inc (OMCL), noting its current valuation score of 6.66, ranking 178 out of 200 in the Healthcare Equipment & Supplies industry. The company's P/E ratio stands at 91.94, which is significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company.
